XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Sales $ 16,657 $ 15,962 $ 48,544 $ 45,485
Costs, Expenses and Other        
Cost of sales 4,080 4,264 11,365 12,214
Selling, general and administrative 2,731 2,519 7,952 7,700
Research and development 5,862 3,307 13,354 20,904
Restructuring costs 56 126 258 344
Other (income) expense, net (162) 126 (151) 388
Total Costs, Expenses and Other 12,567 10,342 32,778 41,550
Income Before Taxes 4,090 5,620 15,766 3,935
Taxes on Income 929 870 2,377 2,332
Net Income 3,161 4,750 13,389 1,603
Less: Net Income Attributable to Noncontrolling Interests 4 5 15 12
Net Income Attributable to Merck & Co., Inc. $ 3,157 $ 4,745 $ 13,374 $ 1,591
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.25 $ 1.87 $ 5.28 $ 0.63
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.24 $ 1.86 $ 5.26 $ 0.62